Home › Chronic Progressive Multiple Sclerosis › NCT07840326

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Who can join

Ages 18 to 70 · All sexes

Inclusion Criteria:

1. Aged 18-70, inclusive
2. Diagnosis of PPMS or non-active SPMS
3. No MS relapses in the past 2 years
4. Evidence that MS has continued to get worse over time
5. A level of disability that fits the study requirements

Exclusion Criteria:

1. Use of certain medications or treatments before the study, or need for these treatments during the study
2. Current participation in another research study
3. Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk
4. Certain serious or unstable medical conditions that could make the study unsafe
5. Active infection, recent infection, or a history of repeated infections

Additional inclusion and exclusion criteria are outlined in the full study protocol.

About the study

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

What is being tested

• SUN-627 (drug)
• Placebo (other)

Sponsor: Sundance Biosciences, Inc. · Participants: 20 · Started: 2026-10

Contact the study team

• Chetan Gandhy, MD · Phone: 650-442-3187

Official record on ClinicalTrials.gov — NCT07840326

Locations in the U.S.

Conditions

• Chronic Progressive Multiple Sclerosis
• Multiple Sclerosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.